Autonomous driving domain controllers maker iMotion Automotive opened at HK$29.55in their Wednesday trading debut, 0.3% lower than their IPO price of HK$29.65.

The latest: Autonomous driving domain controllers maker iMotion Automotive Technology (Suzhou) Co. Ltd. (1274.HK) opened at HK$29.55in their Wednesday trading debut, 0.3% lower than their IPO price of HK$29.65, giving the company a market capitalization of about HK$3 billion ($384 million).

Looking up: The local portion of the company’s public offering in Hong Kong was oversubscribed by about 6.5 times, which is not a bad performance in the recent quiet stock market of Hong Kong.

Take Note: The company raised HK$595 million in net proceeds from the share sale, lower than the market rumor of up to HK$2.34 billion earlier this year.

Digging Deeper: Founded in 2016 by Song Yang, a renowned Chinese engineering expert, iMotion specializes in autonomous driving solutions and has received at least eight rounds of investment prior to its IPO, reaching a valuation of 3.3 billion yuan ($466 million) by its last round of funding. The company has been a non-exclusive supplier of autonomous driving solutions to Geely’s Zeekr electric vehicle (EV) brand since June 2021. Geely provided 53% of iMotion’s revenue in 2021, but the figure swelled to 96.4% and was roughly the same at 95% in the first half of this year, reflecting its heavy reliance on Geely.

Market Reaction: iMotion spent most of Wednesday morning below its IPO price and closed at HK$29.45 at the midday break, 0.7% lower than its IPO price.

Translation by A. Au

Have a great investment idea but don’t know how to spread the word? We can help! Contact us for more details.

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

The loss-making developer of cancer immunotherapies raised just enough financing last year to cross the valuation threshold for a Hong Kong listing.

Sunho Biologics gets green light for downsized IPO

The loss-making developer of cancer immunotherapies raised just enough financing last year to cross the valuation threshold for a Hong Kong listing Key Takeaways: Sunho Biologics has no revenue or…